Free Trial

Upstream Bio (UPB) News Today

$25.46 -0.48 (-1.85%)
(As of 11/15/2024 ET)
Upstream Bio, Inc. stock logo
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th
Upstream Bio's (NASDAQ:UPB - Get Free Report) quiet period will expire on Wednesday, November 20th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Upstream Bio Inc UPB
Upstream Bio, Inc. stock logo
Brokers Set Expectations for Upstream Bio Q4 Earnings
Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Upstream Bio in a research report issued on Thursday, November 7th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($
Upstream Bio (NASDAQ:UPB) Now Covered by William Blair
William Blair Estimates Upstream Bio Q4 Earnings
Upstream Bio, Inc. stock logo
William Blair Weighs in on Upstream Bio Q4 Earnings
Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Analysts at William Blair issued their Q4 2024 earnings per share (EPS) estimates for Upstream Bio in a report issued on Tuesday, November 5th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.42) per share for the
Test tubes on blue background — Photo
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
Upstream Bio, Inc. stock logo
Upstream Bio (NASDAQ:UPB) Earns Overweight Rating from Analysts at Piper Sandler
Piper Sandler initiated coverage on shares of Upstream Bio in a report on Tuesday. They issued an "overweight" rating and a $75.00 price target on the stock.
Get Upstream Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter.

There is a little known company that is changing warfare (Ad)

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

UPB Media Mentions By Week

UPB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

UPB
News Sentiment

0.48

0.56

Average
Medical
News Sentiment

UPB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

UPB Articles
This Week

10

4

UPB Articles
Average Week

Get Upstream Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:UPB) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners